LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

September 06, 2022 | Last Trade: US$21.98 0.15 -0.68

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference
Fireside chat date: Monday, September 12, 2022
Fireside chat time: 1:40 p.m. ET
Location: Sheraton Hotel, New York, NY

H.C. Wainwright 24th Annual Global Investment Conference
Presentation date: Wednesday, September 14, 2022
Presentation time: 9:00 a.m. ET
Location: Lotte New York Palace Hotel, New York, NY

A live webcast of the presentations will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, a replay of the events can be found on the Talaris website.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(617) 903-8783

Investor Contact
Chris Brinzey
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
(339) 970-2843


Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page